Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1988;35(5):467-74.
doi: 10.1007/BF00558240.

Effects of disopyramide on repolarisation and intraventricular conduction in man

Affiliations
Clinical Trial

Effects of disopyramide on repolarisation and intraventricular conduction in man

K Endresen et al. Eur J Clin Pharmacol. 1988.

Abstract

Right ventricular repolarisation and refractoriness after therapeutic doses of disopyramide have been studied in 10 patients with coronary artery disease by recording monophasic action potentials (MAP) during programmed stimulation. Using 2 catheters, with the tip of one in the apex and the other in the outflow tract of right ventricle, conduction intervals for propagation of stimuli in the ventricle were also measured. Disopyramide increased the duration of MAP signals at 90% repolarisation (MAP90), the QT-interval and the right ventricular effective refractory period (V-ERP). The ratio refractoriness/action potential duration was slightly increased. Early premature action potentials were more markedly prolonged in relation to steady-state action potentials. The differences between the shortest and longest premature action potentials, however, were not changed significantly. The conduction intervals of the normal and premature paced beats were significantly prolonged. The observed effects of disopyramide on conduction and action potential duration may be of major importance for its effect on termination and slowing ventricular tachycardias. Its influence on the duration of premature action potentials in man is consistent with the results of in vitro studies.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Br Heart J. 1985 Mar;53(3):328-34 - PubMed
    1. J Pharmacol Exp Ther. 1985 May;233(2):304-11 - PubMed
    1. Eur Heart J. 1986 Jan;7(1):34-41 - PubMed
    1. Am Heart J. 1981 Nov;102(5):864-71 - PubMed
    1. Circulation. 1983 Jan;67(1):38-45 - PubMed

Publication types

LinkOut - more resources